These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38579770)

  • 1. From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity.
    Kistkins S; Moser O; Ankudovičs V; Blizņuks D; Mihailovs T; Lobanovs S; Sourij H; Pfeiffer AFH; Pīrāgs V
    Endocr Connect; 2024 May; 13(5):. PubMed ID: 38579770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
    Soni H
    Med Hypotheses; 2016 Oct; 95():5-9. PubMed ID: 27692167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.
    Tilinca MC; Tiuca RA; Burlacu A; Varga A
    Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34209532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
    Deol H; Lekkakou L; Viswanath AK; Pappachan JM
    Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review).
    Tilinca MC; Tiuca RA; Niculas C; Varga A; Tilea I
    Exp Ther Med; 2021 Oct; 22(4):1167. PubMed ID: 34504612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical Management of Diabesity: Do We Have Realistic Targets?
    Pappachan JM; Viswanath AK
    Curr Diab Rep; 2017 Jan; 17(1):4. PubMed ID: 28101792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives.
    Reed J; Bain S; Kanamarlapudi V
    Diabetes Metab Syndr Obes; 2021; 14():3567-3602. PubMed ID: 34413662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy.
    Tschöp M; Nogueiras R; Ahrén B
    Diabetologia; 2023 Oct; 66(10):1796-1808. PubMed ID: 37209227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies in the treatment of 'diabesity': beyond GLP-1.
    Tharakan G; Tan T; Bloom S
    Trends Pharmacol Sci; 2011 Jan; 32(1):8-15. PubMed ID: 21130506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-based therapy: Past, present and future.
    Patil M; Deshmukh NJ; Patel M; Sangle GV
    Peptides; 2020 Mar; 127():170296. PubMed ID: 32147318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
    Tran KL; Park YI; Pandya S; Muliyil NJ; Jensen BD; Huynh K; Nguyen QT
    Am Health Drug Benefits; 2017 Jun; 10(4):178-188. PubMed ID: 28794822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
    Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
    Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological antagonism of the incretin system protects against diet-induced obesity.
    Svendsen B; Capozzi ME; Nui J; Hannou SA; Finan B; Naylor J; Ravn P; D'Alessio DA; Campbell JE
    Mol Metab; 2020 Feb; 32():44-55. PubMed ID: 32029229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.